Topics

Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

19:00 EST 3 Dec 2019 | AAAS

(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies.

Original Article: Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

NEXT ARTICLE

More From BioPortfolio on "Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...